Katherine, B50, for Treatment of Adjuvant HER2 Positive Breast Cancer

Investigator: Jenny Chang, MD

Study Coordinator: Toniva Boone

Status: Open Not Enrolling

ClinicalTrials.gov Number: NCT01772472

Phone: 713.441.0686

IRB Number: Pro00008985


This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in the breast or axillary lymph nodes following preoperative therapy. Eligible patients will be randomized to receive either trastuzumab emtansine 3.6 mg/kg or trastuzumab 6 mg/kg intravenously every 3 weeks for 14 cycles. Radiotherapy and/or hormone therapy will be given in addition if indicated.
More to Explore